Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with endocrine therapy/ET, significantly improved overall survival/OS in patients with hormone receptor-positive/HR+, HER2-negative, high-risk early breast cancer.
The results came from the primary OS analysis of the Phase 3 monarchE trial, which enrolled 5,637 adults across 38 countries. The study specifically focused on a high-risk population. The trial found that a 2-year course of Verzenio plus ET provided a statistically significant and clinically meaningful improvement in OS compared to ET alone.
A 7-year landmark analysis also showed sustained benefits in invasive disease-free survival/IDFS and distant relapse-free survival/DRFS, reinforcing the drug’s effectiveness. The safety profile of Verzenio remained consistent with previous reports, with all patients having completed or discontinued the two-year treatment regimen.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the US, Europe, China, Japan, and internationally.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
